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Abstract
Interferons (IFNs) are critical determinants in immune-competence and autoimmunity, and are endogenously regulated by a
low-level constitutive feedback loop. However, little is known about the functions and origins of constitutive IFN. Recently,
lipopolysaccharide (LPS)-induced IFN was implicated as a driver of necroptosis, a necrotic form of cell death downstream of
receptor-interacting protein (RIP) kinase activation and executed by mixed lineage kinase like-domain (MLKL) protein. We
found that the pre-established IFN status of the cell, instead of LPS-induced IFN, is critical for the early initiation of
necroptosis in macrophages. This pre-established IFN signature stems from cytosolic DNA sensing via cGAS/STING, and
maintains the expression of MLKL and one or more unknown effectors above a critical threshold to allow for MLKL
oligomerization and cell death. Finally, we found that elevated IFN-signaling in systemic lupus erythematosus (SLE)
augments necroptosis, providing a link between pathological IFN and tissue damage during autoimmunity.
Introduction
Necroptosis is a form of necrotic cell death that occurs
downstream of receptor-interacting protein kinases (RIP1/
RIP3) activation and disruption of the plasma membrane by
the pseudokinase mixed lineage kinase like-domain
(MLKL) [1–3]. If virus infection inhibits apoptosis,
necroptosis becomes a secondary mode of cell death to limit
viral replication [4, 5]. In the laboratory, the use of the pan-
caspase inhibitor zVAD with TNFα stimulation drives
RIP3/MLKL dependent necroptosis [4, 6]. Recently,
necroptosis was shown to occur downstream of toll-like
receptor (TLR) stimulation with zVAD. TLR3/4 are unique
in inducing necroptosis via a common endosomal adaptor,
TRIF (TIR-domain-containing adapter-inducing interferon-
β) [6, 7] independently of TNFα. Upon engagement of
TLR3/4, TRIF interacts with RIP1/RIP3 via RHIM
domains, an event critical for necroptosis [7–9]. Notably,
activation of TLR3/4 also induces interferon (IFN) pro-
duction through TRIF [10]. With the ﬁnding that type I IFN
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Fig. 1 Constitutive type I interferon (IFN-I) signaling is required for initiation of necroptosis. a, b Propidium iodide incorporation as a readout of
cytotoxicity, measured every 15min following LPS/zVAD treatment of BMDMs of indicated genotype. cWestern blot of indicated proteins of resting
BMDMs from B6 and Ifnb−/− with or without overnight interferon treatment (2.5 IU IFNβ/ml). d Treatment scheme for overnight or 1 h treatment of
BMDMs with 2.5 IU/ml of recombinant IFNβ. e Viability of B6 and Ifnb−/− BMDMs measured 6 h after LPS /zVAD treatment. f Treatment scheme
for overnight or 1 h antibody treatment of B6 BMDMs. gWestern blot for indicated proteins from B6 BMDMs treated with antibodies as in (f) before
stimulation with 200 IU/ml IFNβ for 30min. h, i Propidium iodide incorporation of B6 BMDMs treated with LZ and antibody pre-treatment for 36 h
(h) or 1 h (i) as in (f). j Propidium iodide incorporation over 22 h of B6 BMDMs treated with LPS/zVAD or TNF (50 ng/ml)/zVAD (50 μM) and Ifnb
−/− BMDMs treated with TNF/zVAD. k, l Cytotoxicity measurement at 7 h (k) or 20 h (l) from B6 and Ifnb−/− BMDMs treated with TNF/zVAD with
IFN pre-treatment as in (d). All LPS/zVAD treatments were: LPS (10 ng/ml) and zVAD (50 μM/ml). In all cases of IFNβ pre-treatment (overnight or
1 h), the IFNβ is washed away before addition of experimental conditions. Time point cytotoxicity quantiﬁcation ± SD from three independent
experiments compared using student two tailed t-test: ns non-signiﬁcant (p > 0.05); *p < 0.05; **p < 0.01; ***p < 0.001. All western blot and kinetic
cytotoxicity data are representative of three or more experiments. See related supplementary Figure 1
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receptor deﬁcient cells are resistant to TLR3/4 mediated
necroptosis, TRIF was attributed the additional role of
mediating necroptosis via IFN induction [11, 12].
Type I interferons (IFN-I) comprise a family of 14 α
isoforms and one β, κ, ω, and δ isoform each, all of which
bind a common heterodimeric receptor, IFN-αR1 and IFN-
αR2 (IFNAR) [13]. IFNs regulate host immune responses by
binding the receptor and activating STAT1/2 transcription
factors to regulate a diverse family of genes termed interferon
stimulated genes (ISGs) [14]. IFN-I is induced downstream
of cytosolic nucleic acid sensing or endosomal TLRs. In
contrast, constitutive IFN-I signaling in the resting state is
less characterized, despite having been detected in human
and mouse cells including MEFs [15], B cells, and macro-
phages [14]. It has been suggested that constitutive IFN
sustains the expression of JAKs, STATs, and other IFN-I
signaling components. Another function of constitutive
IFN-I is to maintain basal levels of immune-related genes to
enable a rapid response to viral infection [16].
Sufﬁcient IFN signaling is critical for host defense to
avoid lethal viral and mycobacterial infections such as in
STAT1 deﬁcient individuals [17]. In contrast, excessive
IFN has been linked to pathology in multiple autoimmune
diseases including lupus, psoriasis, Sjogrens, dermatomyo-
sitis, and type I diabetes [18]. In the case of inter-
feronopathies including Aicardi–Goutières syndrome and
STING-associated vasculopathy with onset in infancy
(SAVI), IFN directly drives disease [19]. Recently,
necroptosis has been linked to both IFN signaling and
autoimmune disease [20, 21]. Although IFNAR-deﬁcient
cells are resistant to TLR-induced necroptosis, the
mechanism underlying this protection as well as any con-
nection of these ﬁndings to autoimmunity remains unclear.
In this study, we found that constitutive IFN signaling is
crucial for the initiation of necroptosis via the endogenous
activity of the cytosolic DNA sensing pathway cGAS/
STING. Our ﬁndings prompt the model that constitutive
IFN signaling drives the steady-state expression of MLKL
to enable a rapid necroptosis response.
Results
Constitutive IFN signaling licenses necroptosis in
macrophages
To measure cytotoxicity, we monitored the kinetics of
propidium iodide uptake in real time, with LPS and
zVAD (LZ) treatment (Fig. 1a). Compared to wild-type
cells, BMDMs from either kinase inactive RIPK1
Rip1D138N/D138N, Mlkl−/− (Fig. 1a) or RIP3 RHIM domain
mutant (Ripk3ΔR/ΔR) mice (Figure S1A) were resistant to
LPS/ zVAD cytotoxicity.
The role of IFN in necroptosis has been studied using
IFNAR-deﬁcient animals which are unresponsive to both
inducible (stimulation dependent) and constitutive (resting
state) IFN [22]. To distinguish between inducible and
constitutive IFN, we used Ifnb−/− BMDMs, which were
completely resistant to LZ-induced necroptosis (Fig. 1b). In
the resting state, Ifnb−/− BMDMs had lower ISG expres-
sion, including STAT1 and STAT2 (Fig. 1c, Figure S1B),
and Isg15, Irf7 and Mx1 mRNA (Figure S1C). This ISG
deﬁciency can be rescued by overnight treatment with a low
dose (2.5 IU/ml) of recombinant IFNβ (Fig. 1c, Figure S1B,
C). The reduction of ISG expression at both the mRNA
and protein level is consistent with low-constitutive IFN in
Ifnb−/− BMDMs. Unlike STAT1, levels of RIP1, RIP3, and
IRF3 proteins were not substantially affected by constitutive
IFN (Fig. 1c, Figure S1B). In agreement with recently
published work [22], we observed a reduction of MLKL
levels in IFN-deﬁcient BMDMs. This reduction in MLKL
expression in Ifnb−/− BMDMs was rescued with low dose
(2.5 IU/ml) of recombinant IFNβ treatment overnight
(Figure S1D).
To study the role of constitutive IFN on cell viability, we
used overnight (10 h) or 1-h pre-treatment of cells with low
dose (2.5 IU/ml) IFNβ prior to stimulation with LZ
(Fig. 1d). At 6 h of LZ stimulation, only overnight IFNβ
treatment sensitized Ifnb−/− BMDMs to necroptosis
(Fig. 1e). We observed rapid upregulation of ISGs with IFN
treatment (Figure S1E), suggesting that time is required for
ISGs to be translated. We also used IFNAR blocking anti-
body to inhibit either stimulus-induced IFN (−1 h pre-
treatment) or constitutive IFN (−36 h Antibody) (Fig. 1f).
Both 1 h and 36-h treatment of blocking antibody inhibited
STAT1 phosphorylation in B6 BMDMs when stimulated
with IFNβ (Fig. 1g). However, only 36-h pre-treatment
decreased total STAT1 (Fig. 1g). Correspondingly, 36-h
blockade of IFNAR abolished necroptosis in B6 BMDMs
(Fig. 1h), whereas 1-h blockade did not affect necroptosis
(Fig. 1i).
Extending our ﬁndings to other models of necroptosis,
we treated BMDMs with TNF/zVAD (TZ) and observed
that cytotoxicity is slower than with LZ necroptosis
(Fig. 1j). As with LZ-induced necroptosis, Ifnb−/− BMDMs
were resistant to TZ-induced death (Fig. 1j). Interestingly,
unlike LZ-induced necroptosis, TZ-necroptosis was sensi-
tized by either overnight or 1 h IFNβ pre-treatment Ifnb−/−
BMDMs (Fig. 1k, l). Correspondingly, 24 h of IFNAR
blockade protected against TZ-induced cell death, whereas
1 h did not (Figure S1F). We also investigated the SMAC-
mimetic (SM) and zVAD model of necroptosis, which
unlike TNF and zVAD, resulted in the same kinetics and
magnitude of cell death as LPS and zVAD treatment (Fig-
ure S1G). Like LZ treatment, Ifnb−/− BMDMs were resis-
tant to SM+ zVAD-induced cytotoxicity and could be
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sensitized to necroptosis after overnight treatment with low
dose IFNβ (Figure S1H).
Extending our ﬁndings to human monocyte derived
macrophages (MDM), we conﬁrmed that LPS and zVAD
induces RIPK-dependent cell death using Necrostatin-1
(Figure S1I). Next, we blocked IFN signaling with the
JAK1/2 inhibitor Ruxolitinib (Rux) in MDMs either 1-h or
36 h prior to LZ stimulation. Chronic Rux treatment
downregulated IRF7 expression in resting cells (Fig-
ure S1J). Furthermore, 36 h but not 1 h Rux pre-treatment
downregulated total STAT1 levels, although both treat-
ments effectively inhibited STAT1 phosphorylation in
response to exogenous IFNβ (Figure S1K). Rux treatment
did not affect MLKL levels in MDMs (Figure S1K). Con-
sistent with mouse macrophages, chronic Jak inhibition
protected MDMs against LZ-induced necroptosis (Fig-
ure S1L, M). Treatment of MDMs with IFNAR blocking
antibody partially inhibited STAT1 phosphorylation in
response to exogenous IFNβ (Figure S1N). However, 36-h
treatment with IFNAR blocking antibody did not reduce
total STAT1 levels (Figure S1N) or IRF7 expression
(Figure S1O). Accordingly, 36 h IFNAR blocking antibody
did not protect human MDMs from LZ treatment
(Figure S1P).
The endosomal TLR4 adaptor TRIF initiates
necroptosis independently of IFNβ induction
TRIF (encoded byTicam1), a key TLR4 adaptor, is required
for both LPS-induced IFN (Fig. 2a) and LPS/zVAD driven
cell death (Fig. 2b). During LZ-induced necroptosis, TRIF
is known to interact with RIP1/RIP3 via RHIM domain
interactions [7]. The resistance of Ticam1−/− BMDMs to
cell death was attributed to their inability to produce IFN
upon LPS stimulation [11], leading to a model that
necroptosis can be driven by TRIF-mediated IFN. In B6
BMDMs, we found that IFNβ, even when used at supra-
physiologic doses of up to 4000 U/ml, is not sufﬁcient to
drive necroptosis in the context of caspase inhibition
(Fig. 2c). To determine whether TRIF dependent IFN pro-
duction is necessary for LPS-induced necroptosis, we trea-
ted B6 and Ticam−/− BMDMs with high-dose exogenous
Fig. 2 The endosomal TLR4 adaptor TRIF initiates necroptosis inde-
pendently of LPS-induced IFNβ. a Supernatant IFNβ cytokine mea-
sured by ELISA from B6 and Ticam1−/− BMDMs stimulated with
LPS/zVAD for 6 h. b Propidium iodide incorporation following LPS/
zVAD treatment of B6 and Ticam1−/− BMDMs as a readout of
cytotoxicity. c Cytotoxicity by PI incorporation of B6 BMDMs treated
for 20 h with LPS/zVAD or varying doses of IFNβ and zVAD. d
Propidium iodide incorporation of B6 and Ticam1−/− BMDMs 6 h
following LPS/zVAD or SM (1 nM)/zVAD treatment with or without
200 IU IFNβ. e Quantitative PCR of Irf7, Isg15, and Mx1 mRNA
relative to Gapdh from resting B6, Ifnar−/− and Ticam1−/− BMDMs.
All LPS/zVAD treatments were: LPS (10 ng/ml) and zVAD
(50 μM/ml). Time point cytotoxicity quantiﬁcation ± SD from three
independent experiments compared using student two tailed t-test: ns
is non-signiﬁcant (p > 0.05); *p < 0.05; **p < 0.01; ***p < 0.001. All
qPCR and kinetic cytotoxicity data are representative of three or more
experiments. See related supplementary Figure 2
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IFNβ (200 U/ml) concurrent with LZ stimulation (Fig. 2d)
and found no sensitization of cell death. Furthermore, we
found that TRIF deﬁcient cells were fully sensitive to TLR-
independent, SM induced necroptosis (Fig. 2d). Ticam1−/−
BMDMs also exhibited normal levels of ISGs at steady
state (Fig. 2e).
The discrepancy between our data and published reports
regarding the necroptotic potential of (IFN+ zVAD)
treatment may be explained by endotoxin contamination
of BSA, a carrier frequently used to dilute recombinant
IFN. We re-constituted IFN in 0.1% BSA from either
endotoxin free BSA or Fisher brand BSA to a concentration
of 10 IU IFNβ/ml and measured cell death (Figure S2A)
and TNF production (Figure S2B) with IFN/zVAD treat-
ment, both of which were un-detectable with endotoxin
free BSA.
336 J. Sarhan et al.
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The DNA sensing pathway cGAS/STING is required
for constitutive interferon production
Aberrant DNA presence, either from the nucleus [23],
mitochondria [24], or lysosomes [25], can activate cytosolic
DNA sensing via cGAS and STING to upregulate IFN.
Indeed, BMDMs lacking STING and the DNA sensor cGAS
had reduced levels of Isg15, Irf7, and Mx1 mRNAs and low
levels of STAT1 protein (Fig. 3a, b; Figure S3A, B). Con-
sistent with the defect in ISG signature, STING- and cGAS-
deﬁcient BMDMs exhibited resistance to LZ-induced early-
onset (6 h) necroptosis (Fig. 3c), which was not due to a
deﬁciency in RIP1, RIP3, or Ticam1 expression
(Figure S3C).
Interestingly, untreated Sting−/− BMDMs became sen-
sitized to cytotoxicity over time, in contrast to the complete
resistance of Ifnb−/− BMDMs (Fig. 3d). We observed
STAT1 phosphorylation in response to LZ treatment in
Sting−/− BMDMs, despite low STAT1 (Fig. 3e). Sting−/−
and cGAS−/− BMDMs were next stimulated with LZ in the
presence of IFNAR blocking antibody MAR1 or isotype
control antibody (antibodies were added 1 h prior to LZ
stimulation). Blocking IFNAR during LZ stimulation pro-
tected both Sting−/− and cGAS−/− BMDMs from necrop-
tosis, but did not affect cell death in B6 BMDMs (Fig. 3f;
Figure S3D). Additionally, we found that Sting−/− and
cGAS−/− BMDMs were completely resistant to TNF/
zVAD-induced cell death (Figure S3E, F).
Extending our ﬁndings to TLR3 mediated necroptosis
with polyinosinic-polycytidylic acid (pI:C) and zVAD,
Ifnar−/− BMDMs were resistant to cell death, and Sting−/−
and cGAS−/− BMDMs were kinetically delayed
(Figure S3G).
We additionally found that IFNβ production is dampened
in Sting−/− BMDMs compared to B6 macrophages in
response to both LPS and LZ (Figure S3H, I), but this effect
of constitutive IFN did not apply to TNFα (Figure S3J, K).
Low IFN-signaling status confers resistance to
necroptosis in MOLF/Ei macrophages
We previously reported that resistance to necroptosis in
peritoneal macrophages of wild-derived MOLF mice are
conferred by downregulation of the deubiquitinase CYLD
[26]. Like peritoneal macrophages, MOLF BMDMs were
also resistant to LZ-induced necroptosis (Figure S3L),
however uniform CYLD expression (Figure S3M) sug-
gested another mechanism for resistance to necroptosis.
Despite low levels of ISGs, (Fig. 3g), MOLF macrophages
readily underwent STAT1 phosphorylation in response to
exogenous IFNβ1 (Figure S3N). Like other constitutive IFN
deﬁcient cells, MOLF BMDMs exhibited slow necroptosis
kinetics, resembling Sting−/− and cGAS−/− BMDMs
(Fig. 3f), and can be sensitized to necroptosis with over-
night IFN priming (Fig. 3h). Similarly, IFNAR blockade
during LZ stimulation prevented late time point sensitiza-
tion to necroptosis in MOLF macrophages (Fig. 3i).
To examine the contribution of the hypomorphic MOLF
allele of Sting [27], we tested BMDMs from mice that are
congenic for the MOLF allele of Sting on the C57BL/6
background (B6-StingM/M) for cell death and IFN status.
Indeed, we observed low-constitutive IFN in B6-StingM/M
BMDMs (Fig. 3j; Figure S3O) and protection from
necroptosis (Fig. 3k).
Interferon receptor signaling is required for RIP1
and RIP3 degradation and MLKL S345
phosphorylation in BMDMs
To determine the step at which constitutive IFN is needed
for LZ necroptosis, we looked at the initiating events in LPS
signaling, including TLR4 endocytosis followed by
engagement of TRIF and IRF3 phosphorylation [28]. Here
we observed that TRIF dependent Serine 396 IRF3 phos-
phorylation following LPS/zVAD stimulation was similar
in all strains including Ifnb−/− BMDMs (Fig. 4a; Fig-
ure S4A). Additionally, the RIP1 mobility shift suggestive
of phosphorylation [11] was also present in Ifnb−/− (Fig. 4a)
Fig. 3 Cytosolic DNA sensing via cGAS and STING is required for
constitutive interferon production. a Quantitative PCR of Isg15 and
western blot of indicated proteins (b) from resting B6, Ifnb−/−, Ifnar
−/−, Sting−/−, and cGAS−/− BMDMs that were untreated or pre-treated
with IFNβ overnight (2.5 IU IFNβ/ml). c Propidium iodide incor-
poration 6 h following LPS /zVAD treatment of BMDMs, either not
treated with IFN (unprimed), pre-treated with 2.5 IU IFNβ/ml over-
night or 1 h before LPS treatment. d Twenty-two hours time course of
propidium iodide incorporation of B6, Sting−/−, Ifnb−/−, BMDMs
stimulated with LPS/zVAD. e Western blots of pSTAT1 and STAT1
from BMDMs of indicated genotype either unstimulated or 2 h LPS/
zVAD stimulated. f B6 and Sting−/− BMDMs pre-treated 1 h with
MAR1 IFNAR blocking or isotype control antibody and monitored for
LPS/zVAD-induced cytotoxicity. g Quantitative PCR of ISG mRNA
relative to GAPDH mRNA from resting B6, Ifnar−/− and MOLF
BMDMs. h Propidium iodide incorporation 6 h following LPS /zVAD
treatment of B6, Ifnar−/− and MOLF BMDMs with or without over-
night interferon pre-treatment (2.5 IU IFNβ/ml). i Propidium iodide
incorporation during 12 h of stimulation with LZ of B6 and MOLF
BMDMs with or without 1 h MAR1 IFNAR blocking antibody pre-
treatment. j Quantitative PCR of MX1 mRNA relative to GAPDH
mRNA from resting BMDMs of indicated genotype without overnight
2.5 IU IFNβ/ml. k Propidium iodide measurement over 12 h of LPS/
zVAD treatment of B6, N10 congenic B6 StingMOLF/MOLF, and MOLF
BMDMs. All LPS/zVAD treatments were: LPS (10 ng/ml) and zVAD
(50 μM/ml). In all cases of IFNβ pre-treatment (overnight or 1 h), the
IFNβ is washed away before addition of experimental conditions.
Time point cytotoxicity quantiﬁcation ± SD from three independent
experiments compared using student two tailed t-test: ns is non-
signiﬁcant (p > 0.05); *p < 0.05; **p < 0.01; ***p < 0.001. All western
blot and kinetic cytotoxicity data are representative of three or more
experiments. See related supplementary Figure 3
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and dependent on a kinase recruited to either TRIF or
MyD88 (Figure S4B).
To investigate the activity of RIP1 and RIP3, we estab-
lished which LZ-induced modiﬁcations of RIP1 and RIP3
are reversible by the RIP1 inhibitor Nec-1. We found that
RIP1 Serine 166 phosphorylation, as well as depletion of
RIP1 and RIP3 total protein, were reversed by Nec-1
(Figure S4C). We could not detect LPS/zVAD-induced
RIP3 modiﬁcations including the activating phospho serine
232 [29] in B6 BMDMs. We found that Ifnb−/− BMDMs
undergo RIP1 S166 phosphorylation and overnight IFN
treatment, attenuates this phosphorylation (Fig. 4b). Unlike
B6 BMDMs, Ifnb−/− BMDMs do not downregulate RIP1
and RIP3 unless primed overnight with IFN (Fig. 4b). Next
Fig. 4 Interferon receptor signaling is required for MLKL phosphor-
ylation in B6 BMDMs a western blots of pIRF3 (S396), total IRF3,
RIP1, and GAPDH from unstimulated, 30 min LPS or LPS/zVAD
stimulated BMDMs from B6, Ifnb−/−, Ticam1−/− and Myd88−/− mice.
b Western blots of indicated proteins from B6 and Ifnb−/− BMDMs
with or without overnight 2.5 IU/ml IFNβ treated with LPS/zVAD. c
Western blots of RIP1 and RIP3 kinases in BMDMs of indicated
genotypes in NP40 soluble or insoluble fractions. d Western blots of
indicated proteins from B6, Ifnb−/−, and Sting−/− BMDMs treated with
LPS/zVAD for indicated duration of time. e–f Western blots of
phospho MLKL (pMLKL), MLKL and GAPDH from B6 and Infb−/−
BMDMs that were untreated or primed with 2.5 IU IFNβ/ml overnight.
(e) or 1 h (f) and treated with LPS/zVAD. g Non-reducing western blot
featuring MLKL oligomers from B6 and Sting−/− BMDMs (with or
without 2.5 IU/ml IFNβ overnight) treated with LPS /zVAD for indi-
cated times. h B6 and MOLF BMDMs were treated with LPS, LPS/
zVAD or LPS/zVAD/Nec-1 for indicated durations and analyzed for
indicated proteins by western blotting. Nec-1 was used at a con-
centration of 30 μM. i Non-reducing western blot featuring MLKL
oligomers from B6 and MOLF BMDMs treated with LPS /zVAD for
indicated times. All LPS/zVAD treatments were: LPS (10 ng/ml) and
zVAD (50 μM/ml). In all cases of IFNβ pre-treatment (overnight or 1
h), the IFNβ is washed away before addition of experimental condi-
tions. All western blot data are representative of three or more inde-
pendent experiments. See related supplementary Figure 4
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Fig. 5 Critical threshold of MLKL expression determines oligomer-
ization potential. a RNA sequencing of resting BMDMs showing
genes downregulated in Ifnar−/−, Sting−/−, StingMOLF/MOLF, and MOLF
compared to B6 (b) and signiﬁcantly higher in expression compared to
B6. c Western blot of ZBP1 in non-treated or O/N 2.5 IU/ml IFNβ
treated B6 and Ifnb−/− BMDMs. d Six hours time course of viability of
LPS/zVAD treated B6, Zbp1−/−, and Ifnar−/− BMDMs. eWestern blot
of MLKL in non-treated or O/N 2.5 IU/ml IFNβ treated B6 and Mlkl
+/− BMDMs. f Nine hours time course of viability of LPS/zVAD
treated B6 and MLKL+/- BMDMs. g, h Non-reducing western blot
featuring MLKL oligomers from BMDMs of indicated genotype
treated with LPS /zVAD either non-IFNβ primed (g) or treated over-
night with 2.5 IU/ml IFNβ (h). i High-content imaging of endogenous
MLKL in PFA ﬁxed B6 and Ifnb−/− BMDMs treated 2 h with LPS/
zVAD. j, k B6 and Ifnar−/− BMDMs transduced with either empty
virus or MLKL over expressing virus and analyzed for LZ-induced
cytotoxicity (j) and non-reducing western blots for MLKL oligomer-
ization and phosphorylation (k). All LPS/zVAD treatments were: LPS
(10 ng/ml) and zVAD (50 μM/ml). In all cases of IFNβ pre-treatment
(overnight or 1 h), the IFNβ is washed away before addition of
experimental conditions. MLKL signal compared using student two
tailed t-test: ns is non-signiﬁcant (p > 0.05); *p < 0.05; **p < 0.01;
***p < 0.001. All western blot and kinetic cytotoxicity data are
representative of three or more experiments. See related supplementary
Figure 5
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we utilized NP-40 detergent insolublecellular lysates to look
for RIP1 and RIP3 modiﬁcations in amyloid-like “necro-
somes” [30]. Consistent with published reports [31], RIP
modiﬁcations were present in the NP-40 necrosomes in a
RIP kinase dependent manner (Fig. 4c; S4D). RIP1 and
RIP3 modiﬁcations in the necrosomes were not reduced in
Ifnb−/− BMDMs (Fig. 4c).
Moving onto MLKL modiﬁcation, consistent with pub-
lished work [22] we found that MLKL Serine 345 phos-
phorylation is deﬁcient in Ifnb−/− and Sting−/− BMDMs
(Fig. 4d). The loss-of-MLKL phosphorylation in Ifnb−/−
BMDMs was rescued with overnight but not acute low-dose
IFNβ treatment (Fig. 4e, f). Furthermore, we found that 36 h
—but not 1 h—treatment with IFNAR blocking antibody
reduced MLKL phosphorylation (Figure S4F,G). Down-
stream of phosphorylation, MLKL forms oligomers,
detectable by non-reducing SDS-PAGE (Figure S4H).
Consistent with defective MLKL phosphorylation, Sting−/−,
Ifnar−/−, and cGAS−/− BMDMs were deﬁcient in oligo-
merization (Fig. 4g; Figure S4I,J).
On the C57BL/6 genetic background, constitutive IFN is
required upstream of MLKL phosphorylation. In contrast to
this, MOLF BMDMs, robustly phosphorylated MLKL,
even in the absence of constitutive IFN (Fig. 4h; Fig-
ure S4K). Interestingly, MOLF BMDMs only weakly oli-
gomerize MLKL (Fig. 4i).
Critical threshold of MLKL expression determines
oligomerization
To screen for ISGs in the necroptosis pathway, we com-
pared resting gene expression of B6 and constitutive IFN
deﬁcient BMDMs. We identiﬁed ~80 genes that are com-
monly downregulated in resting Ifnar−/−, Sting−/−, and B6-
StingM/M BMDMs when compared to B6 (Fig. 5a) and ~ 50
genes upregulated in the absence of constitutive IFN
(Fig. 5b). Known inhibitors of necroptosis including Ppm1b
[32], TRAF2 [33], CHIP [34] and components of the
ESCRT machinery [35] are unaltered by constitutive IFN
status (Figure S5A,B).
Sorting genes (FPKM > 4) by differential expression
between B6 and Ifnar−/− BMDMs, we found Zbp1 (Fig-
ure S5C), which can interact with RIP3 to induce necrop-
tosis during development [36, 37] or in response to
inﬂuenza A virus infection [38]. We observed that ZBP1
protein levels depended on constitutive IFN signaling
(Fig. 5c). However, Zbp1−/− BMDMs were not protected
from LPS-induced necroptosis (Fig. 5d) or MLKL phos-
phorylation (Figure S5D). We also checked the ISG
expression status in resting Zbp−/− cells since ZBP1 was
initially characterized as a cytosolic DNA sensor [39], and
found no defect in the basal expression of multiple ISGs in
Zbp1−/− BMDMs (Figure S5E).
MLKL also appears within our genome wide analysis
comparing resting gene expression in constitutive IFN
deﬁcient BMDMs (Figure S5C). Additionally, we have seen
lower baseline expression of MLKL in multiple instances in
(Figs. 1g, 3b, 4d, e, f and Figure S1D,S4F). We found that
BMDMs from MLKL hemizygous animals (Mlkl+/−) were
defective in baseline levels of MLKL (Fig. 5e). Interest-
ingly, Mlkl+/− BMDMs were resistant to both LPS+ zVAD
(Fig. 5f) and SM-164+ zVAD (Figure S5F) induced
necroptosis. We found that Mlkl+/− BMDMs were not
deﬁcient in MLKL phosphorylation (Figure S5G), but were
deﬁcient in MLKL oligomerization (Fig. 5g), which can be
rescued with low-dose IFNβ priming (Fig. 5h).
Imaging endogenous MLKL we found a gradient of
expression in resting cells, which is signiﬁcantly lower in
Ifnb−/− compared to B6 BMDMs (Fig. 5i). We observed
selective loss-of-cells expressing more MLKL in B6
BMDMs after LPS+ zVAD treatment (Fig. 5i;
Figure S5H).
We also overexpressed MLKL in IFNAR-deﬁcient
BMDMs to see if MLKL alone is sufﬁcient to restore cell
death. There was limited re-sensitization toward cell death
(Fig. 5j; Figure S5I) or oligomerization, even though resting
expression of MLKL was restored in Ifnar−/− BMDMs
(Fig. 5k). Together these results show that adequate MLKL
expression is critical but not sufﬁcient for necroptosis
without IFNAR signaling.
Elevated steady-state IFN predispose cells to
necroptosis
Patients with autoimmunity have elevated circulating IFNs
[40], which we predicted may increase sensitivity to
necrotic stimuli. We found a dose dependent increase in LZ
cytotoxicity with overnight inﬂuenza A virus infection IFNβ
pre-treated B6 BMDMs (Fig. 6a, b). In contrast, exposure to
these same doses of IFNβ 1 h prior to LZ did not affect
cytotoxicity (Fig. 6c, d). Additionally, MLKL expression
and oligomerization was enhanced during overnight of 20
IU/ml IFNβ priming (Fig. 6e), while RIP1 and RIP3 seemed
unaffected. Next, we utilized a well-established model of
lupus of TLR7 overexpression (TLR 7.1) [41]. Using resi-
dent peritoneal cells to more closely capture the in vivo
autoimmune milieu, we found that resident peritoneal cells
from TLR 7.1 animals were more sensitive to LZ-induced
necroptosis and elevated ISGs relative to littermate controls
(Fig. 6f, g). Additionally, we observed that MLKL
expression was higher in resting TLR 7.1 resident peritoneal
cells (Fig. 6h). ACTIN depletion, associated with necrotic
cell death was also more pronounced in TLR 7.1 cells. We
next primed TLR7.1 littermate control resident peritoneal
with 200 IU IFNβ overnight, and observed an elevated
necroptosis response (Fig. 6i). We also found that TLR7.1
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BMDMs similarly exhibited higher necroptosis and ISGs
compared to littermate controls (Fig. 6j, k). Furthermore,
MLKL expression is elevated in resting TLR 7.1 BMDMs
and oligomer formation is initiated faster and appears more
robust (Fig. 6l). Additionally, BMDMs from TLR 7.1 lit-
termate controls (LM) can be sensitized to undergo maximal
cell death with as little as 20 IU IFNβ, for 8 h prior to LZ
stimulation (Fig. 6m). Together, these results show that
elevated IFN-signaling, such as in the case of auto-
immunity, can sensitize cells to necroptosis.
Discussion
Our ﬁndings prompt a new model of the necroptosis path-
way (Fig. 7). During homeostatic cellular turnover, DNA,
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possibly from DNA damage-repair [23] or mitochondrial
stress [24], activates the cGAS/STING pathway leading to
constitutive IFN production that feeds back onto cells to
sustain expression of many ISGs. MLKL is one such ISG
which must be expressed sufﬁciently to facilitate oligo-
merization (Fig. 5e) and cell death (Fig. 5f). Since MLKL
overexpression could not restore necroptosis in Ifnar−/−
macrophages (Fig. 5j), we postulate the importance of
another ISG for RIPK-dependent phosphorylation of
MLKL to execute necroptosis. Because RIP3 can phos-
phorylate MLKL, it is possible that the ISG(s) in question
serve(s) a scaffolding function to bring together RIP3 and
MLKL for proper necrosome formation [30]. Alternatively,
constitutive IFN upregulate an inhibitor of necroptosis,
though multiple known inhibitors are unaltered by con-
stitutive IFN status (Figure S5A,B). Further investigation of
differentially expressed ISGs by focusing on the intersec-
tions of B6, Ifnar−/− and Sting−/− will be a powerful
approach to identify new regulators of necroptosis.
Previous work showed that caspase inhibition in the
context of viral infection increases constitutive IFN pro-
duction via the STING/cGAS pathway [24, 42, 43]. Ele-
vated constitutive IFN may then function to increase the
necroptosis potential to limit viral replication. Parallel study
in the lab (Liu et al., submitted) found that constitutive IFN
governs the rate of pyroptosis in response to Legionella
pneumophila by maintaining guanylate binding protein
expression. A common theme thus emerges, in which the
role of IFN in both cell death pathways is in maintaining
expression of critical effectors for cell death. For necrop-
tosis, we refer to these ISGs as constitutive IFN-regulated
effectors of necroptosis as CIREN(s). CIREN abundance
determines the rapidity of necroptosis. Macrophages with
sufﬁcient levels of CIRENs undergo necroptosis as early as
2 h after LPS/zVAD. In contrast, lack of baseline expression
of ISGs in MOLF, cGas−/− and Sting−/− BMDMs sig-
niﬁcantly delays onset of cell death despite ability of these
BMDMs to induce IFN. This temporal defect in necroptosis
can be explained by time that is required for de novo
synthesis of CIREN proteins downstream of LPS-induced
IFN feedback. Therefore, not only did we elucidate a role
for constitutive IFN signaling in licensing necroptosis by
maintenance of yet unknown but crucial players of the
pathway, we also discovered that de novo IFN induction
only becomes relevant in cases where constitutive IFN is
lacking, to replenish the abundance of said CIREN(s). We
identiﬁed MLKL as a CIREN, but we and others have
shown that MLKL overexpression in IFNAR-deﬁcient
BMDMs is not sensitizing to necroptosis [22] suggesting
that there are other unknown CIREN(s).
While loss-of-constitutive IFN protected cells from
necroptosis, elevated IFN signaling sensitizes TLR7.1
macrophages to necroptosis, which may be relevant to
elevated IFN levels in human lupus. Necrotic cell death has
been proposed as a mechanism by which release of nuclear
antigens and DAMPs feed the cycle of SLE pathogenesis
[44]. Although, the source of necrotic cell death in lupus is
unclear, we show that high-IFN levels pre-disposes mac-
rophages to necrosis by which nuclear and cytosolic content
can be released. Recent report by the Kelliher group has
shown that hyper-activation of necroptosis leads to auto-
immunity [21]. Here we show the inverse, in which cells
from mice with autoimmunity are more sensitive to
necroptosis (Fig. 6). Further work will be needed to estab-
lish the causality between necroptosis and autoimmunity.
Materials and methods
Reagents
Lipopolysaccharide (LPS) (Escherichia coli 0111:B4) was
purchased from Sigma and used at 10 ng/ml. zVAD.fmk
was purchased from ApexBio and used at 50 μM.
Necrostatin-1 was purchased from Sigma and used at 10
μM. SM-164 was purchased from ApexBio and used at 1
μM. Poly(I:C) was from InvivoGen and used at 25 μg/ml.
Recombinant mouse IFNβ (12400-1) and recombinant
human IFNβ (11415-1) were purchased from PBL Assay
Fig. 6 High levels of type I interferon (IFN-I) predispose cells to
necroptosis. a, b Propidium iodide incorporation of B6 BMDMs at 6 h
(a) or kinetically over 6 h (b) of LPS/zVAD treatment with overnight
pre-treatment of recombinant IFNβ. c, d Propidium iodide incorpora-
tion of B6 BMDMs at 6 h (c) or kinetically over 6 h (d) of LPS/zVAD
treatment with 1 h pre-treatment of recombinant IFNβ. e Western blots
of multiple proteins with LPS/zVAD treatment of B6 BMDMs with
indicated IFNβ pre-treatment. f Propidium iodide incorporation over 4
h of TLR7.1 and littermate control resident peritoneal cells treated with
LPS/zVAD. g Quantitative PCR of ISG mRNA relative to Gapdh from
resting TLR7.1 and littermate control resident peritoneal cells. h
Western blots of multiple proteins with LPS/zVAD treatment of
resident peritoneal cells from TLR 7.1, littermate control and Mlkl−/−
animals. i Propidium iodide incorporation over 6 h of TLR7.1 litter-
mate control resident peritoneal cells either non-primed or 200 IU/ml
IFNβ treated for 1 h or overnight and treated with LPS/zVAD. j
Propidium iodide incorporation over 6 h of TLR7.1 and littermate
control BMDMs treated with LPS/zVAD. k Quantitative PCR ISG
mRNA relative to GAPDH from resting TLR7.1 and littermate control
BMDMs. l Western blots of multiple proteins with LPS/zVAD treat-
ment of BMDMs from TLR 7.1 or littermate control animals. m
Propidium iodide incorporation over 6 h of TLR7.1 littermate control
BMDMs either non-interferon primed or 20 IU/ml IFNβ treated for 4
or 8 h and treated with LPS/zVAD. All LPS/zVAD treatments were:
LPS (10 ng/ml) and zVAD (50 μM/ml). In all cases of IFNβ pre-
treatment (overnight or 1 h), the IFNβ is washed away before addition
of experimental conditions. MLKL oligomers were visualized using
non-reducing western blots. Cytotoxicity data are representative of
three or more experiments. qPCR represent SD from three independent
experiments and statistical signiﬁcance was determined using Student's
two tailed t-test: *p < 0.05; **p < 0.01; ***p < 0.001
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Science and used at various concentrations as indicated. In
all cases of IFNβ pre-treatment (overnight or 1 h), the IFNβ
is washed away before addition of experimental conditions.
Recombinant moue TNF was purchased from PeproTech
and used at a concentration of 50 ng/ml. Ruxolitinib was
purchased from cayman chemical and used at a concentra-
tion of 10 μM. Blocking antibody to mouse IFNAR
(MAR1-5A3) and control IgG were purchased from BD
Pharmingen and used at 20 μg/ml. Blocking antibody to
human IFNAR (#21385–1) and control IgG were purchased
from PBL and used at a concentration of 20 μg/ml.
Recombinant proteins were re-constituted in 0.1% endo-
toxin free BSA from Akron Biotech (AK8917).
Cell viability assays
BMDMs were plated in 96-well plates at 1 × 105 cells per
well in RPMI, 10% FBS, 1%PS. Cells were plated on tissue
culture treated clear bottom plates (Costar 3603) in media
containing 10 μg/mL propidium iodide (Life Technologies,
P3566). TECAN Inﬁnite 200 Pro plate reader was used to
maintain temperature at 37 °C and 5% CO2 during infection.
Propidium iodide uptake was measured every 15 min using
bottom read using 535 nm excitation and 617 nm emission.
Wells containing 0.1% Triton X-100 lysed cells were used
as 100% cytotoxicity controls. Treatment+ zVAD PI
incorporation was relative to treatment alone (LPS+ zVAD
relative to LPS alone). A similar protocol was used pre-
viously [45]. For polyI:C induced necroptosis, kinetic
microscopy was performed using the Cytation3 Imager
(BioTek) and nuclei positive of propidium iodide signal
were enumerated. Plate reading function was not used in
this case, since PI intercalates with polyI:C, generating high
background signal.
Animals
C57BL/6, MOLF/Ei, Ifnar−/− (B6.129S2-Ifnar1tm1Agt/
Mmjax), Trif-/-(C57BL/6J-Ticam1Lps2/J), MyD88-/-
(B6.129P2(SJL)-Myd88tm1.1Defr/J), strains were obtained
from the Jackson Laboratory. Tlr7.1 Tg mice [41] (C57BL/
6-Tg(Tlr7)1Boll) were obtained from Dr. B. Huber (Tufts).
Ifnb−/− were a gift from Dr. S. Vogel (UMaryland).
Trif−/−/MyD88−/−, cGAS−/− and RIP3−/−/Caspase-8−/−
animals were a gift from Dr. K. Fitzgerald (UMass).
RIP3−/−/Caspase-8−/− animals [46] were generated by Dr.
D. Green (St. Jude). RIP1 kinase inactive (Rip1D138N/
D138N) [47] and Mlkl−/− animals were a gift from Dr. M.
Kelliher (UMass). Mlkl−/− [48] animals were generated by
Dr. W. Alexander (Walter and Eliza Hall Institute). Zbp1−/−
mice [49] were a gift from Dr. S. Balachandran. Sting−/−
animals were a gift from Dr. G. Barber (UMiami). RIP3
RHIM domain mutant (Ripk3ΔR/ΔR) mice [50] were a gift
from Dr. Francis Chan. All genetically modiﬁed mice were
Fig. 7 Model for the role of
interferon in necroptosis
Constitutive IFN signaling (left
side, chronologically numbered)
is driven by homeostatic cGAS/
STING activation from cytosolic
DNA sensing. This IFN
signaling loop sustains the
baseline expression of ISGs
(#5). One of these ISGs is
MLKL, which must be present
at adequate levels to allow for
MLKL oligomerization
following phosphorylation.
Total levels of MLKL are
another critical checkpoint of
regulation for necroptosis. The
requirement for constitutive IFN
signaling for cell death is
common to LPS, SMAC-
mimetic and TNF-induced
necroptosis all of which also
require caspase-8 inhibition as
indicated by zVAD
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fully backcrossed to the C57BL/6 background. B6. MOLF-
Tmem173molf (STINGMOLF/MOLF) congenic mice were
established by backcrossing 10 generations to C57BL/628.
All mice were housed in a pathogen-free facility at the Tufts
University School of Medicine and experiments were per-
formed in accordance with regulations and approval of the
Tufts University Institutional Animal Care and Use
Committee.
RNA preparation and analysis
A total of 5 × 105 cells were plated on 24-well TC treated
plates and cells were lysed with Trizol (Invitrogen) fol-
lowed by RNA extraction according to the manufacturer’s
instructions. cDNA was synthesized using M-MuLV
reverse transcriptase, RNase inhibitor, random primers 9,
and dNTPs (New England BioLabs). cDNA was analyzed
for mRNA expression levels using SYBR Green (Applied
Biosystems) and intron spanning primers. Gapdh was used
to normalize mRNA expression and post ampliﬁcation
melting curve analysis was used for all transcripts to verify
speciﬁcity.
Mouse bone marrow derived macrophages (BMDMs)
Bone marrow was isolated by ﬂushing femurs with cold
RPMI. Cell pellets were re-suspended in BMDM differ-
entiating media (RPMI with L-glutamine, 20% FBS, 28% L-
cell conditioned media, 1% Pen-Strep) and cultured for
7 days at 37 °C in 5% CO2 to mature to macrophages.
Matured BMDMs were rested overnight in RPMI contain-
ing 10% FBS, 2% Penn/Strep, in the absence of L-cell
conditioned media prior to experiments.
Human monocyte derived macrophages (MDMs)
De-identiﬁed human peripheral blood was purchased from
the New York Biologics as approved by the Institutional
Review Board and Institutional Biosafety Committee at
Tufts University. Monocytes were obtained from peripheral
blood using the EasySep Direct Monocyte Isolation Kit
from STEMCELL technologies (#19669). Monocytes were
extracted and differentiated into macrophages over the
course of 7 days in RPMI containing 20% FBS, 2% Penn/
Strep, and 100 μg/ml of human M-CSF (PeproTech).
Matured MDMs were rested for 36 h in RPMI containing
10% FBS, 2% Penn/Strep, in the absence of M-CSF prior to
experiments. Similar protocols were used previously [51].
Western blotting
To prepare whole-cell lysates, cells were lysed directly in
1× Laemmli Buffer with 5% β−mercaptoethanol, boiled for
10 min, and incubated on ice for 10 min. Protein lysates
were resolved on a 10% Bis-Tris SDS gel and transferred to
a nitrocellulose membrane. Blocking conditions were TBS-
T with 5% BSA. Primary antibodies were diluted to 1:1000
in TBS-T with 1% BSA, and infrared (700 or 800 nm)
secondary antibodies were diluted 1:30,000. Membranes
were incubated with protein-speciﬁc primary antibodies
overnight at 4 °C followed by 40-min room temperature
incubation with secondary infrared antibodies and imaged
using an Odyssey® CLx Imaging System. Image analysis
was done using Image Studio software. STAT1(#9172),
STAT2 (#72604) pSTAT1-Tyr701(#9167), RIP1
(#D94C12), phospho-RIP1-S166 (#65746), phospho-p38
MAPK-Thr180/Tyr182 (#9211), IRF-3 (#4302), phospho-
IRF-3- Ser396 (#4947) GAPDH (#2118), and ACTIN
(#3700) antibodies were purchased from Cell Signaling.
RIP3 antibody (#2283) was purchased from ProSci. Total
MLKL antibody was purchased from Millipore
(#MABC604). Phospho-MLKL- S345 (#ab196436), and
phospho-RIP3- S227 (#ab209384) antibodies were pur-
chased from Abcam. CYLD antibody (clone 733) was
purchased from Invitrogen. ZBP1 antibody (clone Zippy-1)
was purchased from Adipogen. For visualizing MLKL
oligomers, samples were processed in the same way as for a
standard western blot but Laemmli Buffer was free from β
−mercaptoethanol. MLKL was detected using the same
antibody from Millipore (#MABC604), and anti-rat HRP
(CST #7077) 1:2000 dilution. HRP was developed using
SuperSignal™ West Femto (34095) from Thermo and
visualized using a BioRAD ChemiDoc digital chemilumi-
nescence imager.
High-content imaging
Cells were seeded at a density of 0.5 × 106 cells/cm2 on
MatriPlate 0.17 mm glass bottom plates (DOT Scientiﬁc) in
RPMI containing 10% FBS. At indicated time points post
treatment, cells were ﬁxed for 10 min with 4% paraf-
ormaldehyde, then washed with blocking buffer (10% goat
serum, 2% FBS in PBS) 3× followed by 1 h room tem-
perature incubation with blocking buffer. Overnight 4 °C
incubation with anti MLKL antibody from Millipore
(#MABC604) (1:250 dilution) followed by 3× blocking
buffer wash and 1 h incubation with goat anti-rat AF488
Thermo (#A-11006) (1:250 dilution). Nuclei were counter-
stained with Hoechst [2 μM ﬁnal] Thermo (#62249) for 10
min at room temperature ﬂowed by 3× BPS wash. For
washing procedure, imaging plate was ﬁrst centrifuged at
200×g for 5 min, then plate was dumped to remove liquid
instead of aspiration to avoid removing loosely adhered
cells. A total of 25 ﬁelds at ×20 magniﬁcation were cap-
tured and stitched by the Cytation3 automated microscope,
generating ﬁelds of view with ~3000 cells each for image
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quantiﬁcation. Signal intensity for MLKL was analyzed
with the Gen5 software using MLKL−/− macrophages as
negative controls to determine the non-speciﬁc background
signal intensity.
MLKL overexpression
The open reading frame of murine MLKL was cloned into
pLEX lentiviral plasmid using BamHI and NotI sites. To
reduce the extent of cell death caused by MLKL over-
expression toxicity, the full length CMV promoter of pLEX
was reduced resulting in minimal CMV promoter driving
expression of MLKL. 293T cells were transfected with
lipofectamine 2000 reagent according to manufacturer
suggestions. Brieﬂy, each transfection required a 90%
conﬂuent 10 cm plate of 293T cells in 14 ml DMEM media
(10% FBS, 2% PS). Cells were transfected with 2 μg plas-
mid (MLKL or empty vector), 1.5 μg pSPAX1, 0.5 μg
MD2.G with 12 μl transfection reagent in 200 μl Opti-Mem.
Virus was collected after 48 h 37 °C incubation and sterile
ﬁltered with 0.22 μm syringe ﬁlter to remove cell debris.
Each 10 cm plate of 293T cells produced enough virus to
transduce 3–4 plates of BMDMs. Mouse bone marrow was
plated at 2–3 million undifferentiated cells per 10 cm non-
tissue culture treated petri dish with 14 ml BMDM media
and virus was added during initial plating of bone marrow.
Cells would normally be selected with puromycin at 5 μg/ml
for 48 h starting on day 5; however, we found that pur-
omycin selection affected cell death sensitivity and thus
cells were not puromycin selected for MLKL over-
expression experiments. Cells were counted, re-plated in
complete RPMI on day 7 of differentiation and rested
overnight before experiments.
Next generation sequencing
Total RNA was isolated from resting BMDMs using TRIzol
and used to make a directional cDNA library using TrueSeq
kit. Seventy-ﬁve bp pair-end reads from cDNA libraries
were generated on MiSeq (Illumina) and aligned using
TopHat2 and Cufﬂinks software. Log-transformed values
were displayed by heat map. The data are available at the
National Center for Biotechnology Information Gene
Expression Omnibus:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE83885
Primers
Primers for mouse IRF7: (F) 5′′-CTTCAGCACTTTCTT
CCGAGA-3′, (R) 5′-TGTAGTGTGGTGACCCTTGC-3′;
ISG15: (F) 5′-GAGCTAGAGCCTGCAGCAAT-3′, (R) 5′-
TTCTGGGCAATCTGCTTCTT-3′, MX1: (F) 5′- TCTG
AGGAGAGCCAGACGAT-3′, (R) 5′-ACTCTGGTCCCC
AATGACAG-3′, GAPDH: (F) 5′- GGAGAGTGTTTCCT
CGTCCC-3′, (R) 5′-TTCCCATTCTCGGCCTTGAC- 3′.
TICAM1 (F) 5′- TACCAGCTAAGACCCCTACA-3′, (R)
5′-GTCCCTTTCCAAGGCACCTA- 3′, primers for human
IRF7: (F) 5′-CTTGGCTCCTGAGAGGGCAG-3′, (R) 5′-
CGAAGTGCTTCCAGGGCA-3′; human ISG15: (F) 5′-
TCCTGCTGGTGGTGGACAA-3′, (R) 5′-TTGTTATTCC
TCACCAGGATGCT-3′; human MX1: (F) 5′-GTGCATT
GCAGAAGGTCAGA-3′, (R) 5′-TCAGGAGCCAGCTTA
GGTGT-3′; human GAPDH: (F) 5′-GCTCCTCCTGTTCG
ACAGTCA-3′, (R) 5′-ACCTTCCCCATGGTGTCTGA-3′.
ELISA
Cell free supernatants were analyzed for IFNβ as published
in ref. [51] and TNFα using the DuoSet elisa kit from R&D
(DY410).
Statistical analysis
Values presented as mean ± standard deviation (SD). Error
bars in kinetic viability experiments represent the SD from
the mean of triplicate samples. Error bars in qPCR experi-
ments represent the SD from duplicate samples. Data for
kinetic viability experiments and qPCR are representative of
three or more independent experiments. Time point quan-
tiﬁcations of cytotoxicity represent SD from three inde-
pendent experiments and statistical signiﬁcance was
determined using Student two tailed t-test: ns is non-
signiﬁcant (p > 0.05); *p < 0.05; **p < 0.01; ***p < 0.001.
Comparisons are between two conditions indicated by the
ends of the solid lines.
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